Rokos Capital Management LLP Caribou Biosciences, Inc. Transaction History

Rokos Capital Management LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.58 - $6.25 $6.83 Million - $11.9 Million	-1,907,509 Reduced 69.41%	840,630 $4.82 Million
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $4.68 Million - $9.26 Million	840,630 Added 44.07%	2,748,139 $17.3 Million
Q2 2022 Aug 15, 2022	BUY	$5.1 - $9.74 $5.4 Million - $10.3 Million	1,058,175 Added 124.59%	1,907,509 $10.6 Million
Q1 2022 May 16, 2022	BUY	$8.42 - $15.32 $7.15 Million - $13 Million	849,334 New	849,334 $7.9 Million
Q1 2022 May 16, 2022	SELL	$8.42 - $15.32 $4.8 Million - $8.74 Million	-570,359 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $3.22 Million - $5.13 Million	220,386 Added 62.97%	570,359 $8.6 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $5.51 Million - $10.6 Million	349,973 New	349,973 $8.2 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $96.7M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Rokos Capital Management LLP, based on Form 13F filings with the SEC.

Stay updated on Rokos Capital Management LLP with notifications on news.